Scientists reported evidence linking soluble immune marker dynamics to Huntington’s disease progression. In work from Sweden, sCD30 (TNFRSF8) levels measured in spinal fluid declined steadily as disease advanced, and the trajectory aligned with worsening clinical status. The approach reinforces interest in cerebrospinal-fluid biomarkers that track neurodegenerative progression with better granularity than blood measurements for certain conditions. For trial design, such markers can support enrichment strategies and help reduce reliance on purely clinical endpoints. For biotech developers, immune-related soluble markers may be especially attractive if they can be assayed reproducibly and translated into longitudinal monitoring. The broader implication is that biomarker programs are increasingly moving toward “disease course” readouts rather than cross-sectional diagnosis only.